Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Graybug Vision Inc.

www.graybug.com

Latest From Graybug Vision Inc.

Finance Watch: Deerfield Invests $635m In New York Start-Ups, Pledges $2bn Globally By 2030

Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.

StartUps and SMEs Financing

Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
Deals Financing

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.

Financing Business Strategies

Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • GrayBug Inc.
  • GrayBug LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Graybug Vision Inc.
  • Senior Management
  • Frédéric Guerard, CEO
    Pamela Wapnick, CFO
    Ming Yang, PhD, VP, R&D
    Charles Semba, MD, CMO
  • Contact Info
  • Graybug Vision Inc.
    Phone: (650) 487-2800
    275 Shoreline Dr., Ste. 450
    Redwood City, CA 94065
    USA
UsernamePublicRestriction

Register